Betibeglogene autotemcel (beti-cel) gene therapy for the treatment of Transfusion-Dependent β-Thalassemia (TDT): Updated long-term efficacy and safety results

被引：0

作者：

Kulozik, A. E. ^{[1
]}

Thuret, I ^{[2
]}

Thompson, A. A. ^{[3
]}

Kwiatkowski, J. L. ^{[4
]}

Porter, J. B. ^{[5
]}

Hongeng, S. ^{[6
]}

Yannaki, E. ^{[7
]}

Sauer, M. G. ^{[8
]}

Thrasher, A. J. ^{[9
]}

Lal, A.

Du, L. ^{[10
]}

Colvin, R. A. ^{[11
]}

Walters, M. C. ^{[12
]}

Locatelli, F. ^{[13
]}

机构：

[1] Heidelberg Univ, Univ Med Ctr Children & Adolescents, Heidelberg, Germany

[2] Marseille Univ, Dept Pediat Hematol, Marseille, France

[3] Feinberg Sch Med, Hematol Sect, Chicago, IL USA

[4] Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA USA

[5] UCL, Dept Haematol, London, England

[6] Ramathibodi Hosp, Dept Pediat, Fac Med, Bangkok, Thailand

[7] G Papanicolaou Hosp, Hematol Dept Hematopoiet Cell Transplantat Unit, Gene & Cell Therapy Ctr, Thessaloniki, Greece

[8] Hannover Med Sch, Pediat Hematol & Oncol, Hannover, Germany

[9] Great Ormond St Hosp Sick Children, London, England

[10] UCSF Benioff Childrens Hosp, Oakland, CA USA

[11] Bluebird Bio Inc, Cambridge, England

[12] Univ Calif San Francisco, San Francisco, CA 94143 USA

[13] Osped Pediat Bambino Gesu, Dept Pediat Hematol Oncol, Rome, Italy

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V293

引用

页码：8 / 9

页数：2